Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cerivastatin

K J McClellan1, L R Wiseman, D McTavish

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|April 8, 1998
PubMed
Summary
This summary is machine-generated.

Cerivastatin, a potent HMG-CoA reductase inhibitor, effectively lowers cholesterol by reducing synthesis. It demonstrates superior enzyme affinity and efficacy in reducing LDL-cholesterol compared to other statins.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-grain scintillator screens for proton radiography.

The Review of scientific instruments·2024
Same author

Kondo quasiparticle dynamics observed by resonant inelastic x-ray scattering.

Nature communications·2022
Same author

Physics-informed machine learning for inorganic scintillator discovery.

The Journal of chemical physics·2018
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quantum critical fluctuations in the heavy fermion compound Ce(Ni0.935Pd0.065)₂Ge₂.

Journal of physics. Condensed matter : an Institute of Physics journal·2014
Same author

Anisotropic thermal conductivity in uranium dioxide.

Nature communications·2014
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Hypercholesterolemia is a significant risk factor for cardiovascular disease.
  • HMG-CoA reductase inhibitors (statins) are primary agents for lowering cholesterol.
  • Cerivastatin is a synthetic statin known for its high liver selectivity.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of cerivastatin in managing hypercholesterolemia.
  • To compare the HMG-CoA reductase inhibitory potential of cerivastatin with other statins.
  • To assess potential drug interactions with commonly coadministered medications.

Main Methods:

  • In vitro enzyme inhibition assays comparing cerivastatin with lovastatin, simvastatin, and pravastatin.

Related Experiment Videos

  • In vivo studies in rats and beagle dogs to determine ED50 values for HMG-CoA reductase inhibition.
  • Clinical trial in patients with type IIa hypercholesterolemia assessing lipid profile changes.
  • Drug interaction studies with digoxin, warfarin, cimetidine, and magnesium/aluminium hydroxide.

    • Main Results:

    • Cerivastatin exhibited higher in vitro affinity for HMG-CoA reductase than lovastatin, simvastatin, and pravastatin.
    • In vivo studies showed a lower ED50 for cerivastatin in rats and dogs, indicating greater potency.
    • A daily dose of 0.2 mg cerivastatin significantly reduced LDL-cholesterol, total cholesterol, and triglycerides, while increasing HDL-cholesterol.
    • No significant drug interactions were observed with coadministered medications.

    Conclusions:

    • Cerivastatin demonstrates superior HMG-CoA reductase inhibitory activity compared to other statins.
    • It is effective in improving lipid profiles in patients with type IIa hypercholesterolemia.
    • Cerivastatin possesses a favorable tolerability and drug interaction profile, similar to other statins.